摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Isopropyl-4-aminopyrazolo<3,4-d>pyrimidin | 4014-61-3

中文名称
——
中文别名
——
英文名称
1-Isopropyl-4-aminopyrazolo<3,4-d>pyrimidin
英文别名
4-Amino-1-isopropyl-pyrazolo<3.4-d>pyrimidin;1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine;1-isopropyl-4-amino-pyrazolo[3,4-d]pyrimidine;1-(Propan-2-yl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine;1-propan-2-ylpyrazolo[3,4-d]pyrimidin-4-amine
1-Isopropyl-4-aminopyrazolo<3,4-d>pyrimidin化学式
CAS
4014-61-3
化学式
C8H11N5
mdl
——
分子量
177.209
InChiKey
SATDXXCPAMBXAH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    69.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    杂环系列中的药用化学研究。第26次通讯† ‡
    摘要:
    描述了在3-或4-位具有氨基的吡唑并[3,4-d]嘧啶的合成。为了制备3-氨基衍生物,将4-氯-5-氰基-嘧啶与各种肼缩合。4-氨基-吡唑并[3,4-d]嘧啶是通过使3-氨基-4-碳乙氧基-吡唑与甲酰胺反应,氯化4-羟基-吡唑并[3,4-d]嘧啶并取代卤素而获得的。通过氨基。一些化合物表现出利尿和心脏活性,另一些则抑制肿瘤的生长。
    DOI:
    10.1002/hlca.19590420318
点击查看最新优质反应信息

文献信息

  • 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
    申请人:INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I.
    公开号:US20190185510A1
    公开(公告)日:2019-06-20
    The present disclosure relates to 2′3′ cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    本公开涉及一般式(J)的2′3′环磷酸二核苷酸,其药用可接受盐,其药物组合物以及所述物质与其他药物或药品的组合物。该公开还涉及使用所述化合物治疗或预防可通过STING蛋白调节改变的疾病或状况,如癌症或病毒性、过敏性和炎症性疾病。此外,这些物质可用作疫苗的辅助剂。
  • 3'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
    申请人:INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    公开号:US20190183917A1
    公开(公告)日:2019-06-20
    Provided herein are the 3′3′ cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    本文提供了一般式J的3′3′环磷酸二核苷酸及其药学上可接受的盐、包含它们的制药组合物以及与其他药物或制药品的混合物。本文还涉及使用这些化合物治疗或预防可通过STING蛋白调节改变的疾病或病症,例如癌症或病毒性、过敏性和炎症性疾病。此外,这些物质可以用作疫苗佐剂。
  • 2'2' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
    申请人:INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    公开号:US20190185509A1
    公开(公告)日:2019-06-20
    Provided herein are 2′2′ cyclic phosphonate dinucleotides of formula (J), their pharmaceutically acceptable salts, hydrates or solvates, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, the dinucleotides can be used as adjuvants in vaccines.
    本文提供了式(J)的2′2′环磷酸二核苷酸,它们的药学上可接受的盐、水合物或溶剂化物,以及含有它们的药物组合物和其他药物或制药品的组合物。本文还涉及使用这些化合物治疗或预防STING蛋白调节可改变的疾病或病情,如癌症或病毒性、过敏性和炎症性疾病。此外,这些二核苷酸可以用作疫苗佐剂。
  • OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE
    申请人:MANOHARAN Muthiah
    公开号:US20090281298A1
    公开(公告)日:2009-11-12
    One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.
    本发明的一个方面涉及至少包含一种非天然核碱基的双链寡核苷酸。在某些实施例中,非天然核碱基是二氟基甲苯基、硝基吲哚基、硝基吡咯基或硝基咪唑基。在一个首选实施例中,非天然核碱基是二氟基甲苯基。在某些实施例中,仅有双链寡核苷酸中的两个寡核苷酸链中的一个包含非天然核碱基。在某些实施例中,包含双链寡核苷酸的两个寡核苷酸链独立地包含非天然核碱基。在某些实施例中,寡核苷酸链包括至少一个修饰的糖基团。本发明的另一个方面涉及至少包含一种非天然核碱基的单链寡核苷酸。在一个首选实施例中,非天然核碱基是二氟基甲苯基。在某些实施例中,核苷中天然存在的核苷糖被替换为六碳糖、多环杂基烷基环或环己烯基团。在某些实施例中,寡核苷酸中的至少一个磷酸酯连接被替换为磷酸硫酯连接。
  • OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE
    申请人:MANOHARAN MUTHIAH
    公开号:US20090281299A1
    公开(公告)日:2009-11-12
    One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.
    本发明的一个方面涉及到一种在3'-位点上用磷酰胺基取代的核糖核苷。在某些实施例中,磷酰胺基是一种烷基磷酰胺基。本发明的另一个方面涉及到至少含有一种非磷酸酯连接的双链寡核苷酸。代表性的非磷酸酯连接包括磷酸酯、羟胺、羟基肼、酰胺和氨基甲酸酯连接。在某些实施例中,非磷酸酯连接是磷酸酯连接。在某些实施例中,非磷酸酯连接仅出现在一个链上。在某些实施例中,非磷酸酯连接出现在两个链上。在某些实施例中,配体与包含双链寡核苷酸的寡核苷酸链的其中一个链结合。在某些实施例中,配体与包含双链寡核苷酸的寡核苷酸链的两个链都结合。在某些实施例中,寡核苷酸链包括至少一个修饰的糖基团。本发明的另一个方面涉及到至少含有一种非磷酸酯连接的单链寡核苷酸。代表性的非磷酸酯连接包括磷酸酯、羟胺、羟基肼、酰胺和氨基甲酸酯连接。在某些实施例中,非磷酸酯连接是磷酸酯连接。在某些实施例中,配体与寡核苷酸链结合。在某些实施例中,寡核苷酸包括至少一个修饰的糖基团。
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺